Metformina + Vildagliptina Krka (Metformin Hydrochloride, Vildagliptin)

Metformin Hydrochloride reduces hepatic glucose production and improves peripheral insulin sensitivity. By decreasing the amount of glucose released by the liver and enhancing the response of muscle and fat cells to insulin, it contributes to lower blood glucose concentrations.

The dosage of Metformina + Vildagliptina is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength and frequency according to current treatment guidelines.

Safety in pregnancy and lactation has not been fully established. The medication should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and it must be prescribed by a qualified clinician after careful assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Metformina + Vildagliptina combines a biguanide (metformin) with a DPP‑4 inhibitor (vildagliptin), offering complementary mechanisms: reduced hepatic glucose output and enhanced incretin‑mediated insulin secretion. Compared with metformin alone, the combo provides greater HbA1c reduction, while avoiding the weight gain often seen with sulfonylureas or insulin.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

The medication is taken orally, usually with meals, using a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and should not crush or chew the tablets unless specifically instructed.

The most serious adverse events include lactic acidosis (particularly in patients with renal or hepatic impairment), severe hypoglycaemia when combined with insulin or sulfonylureas, acute pancreatitis, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these occur.

The combination is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or vildagliptin, acute or chronic metabolic acidosis, and in those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease or heart failure.